Kathleen N. Moore, MD
A potential regulatory approval for mirvetuximab soravtansine could herald increased excitement for antibody-drug conjugates overall in the ovarian cancer paradigm, according to Kathleen N. Moore, MD.
Some of the key takeaways about mirvetuximab soravtansine specifically, she added, is that it is a well-tolerated agent by patients. Physicians, however, need to ensure proper assessment for ocular toxicities, which are inclusive with the therapy.
In an interview with OncLive
, Moore, the Jim and Christy Everest Endowed Chair and associate director of clinical research, associate professor, Section of Gynecologic Oncology Director, Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, The University of Oklahoma, discussed the significant unmet needs in the field of ovarian cancer and the recent findings with mirvetuximab soravtansine.
... to read the full story